News|Articles|November 4, 2024
Best Practices, Strategies & Use of Novel Biological Responses for Robust Cell-Based Potency Assays (Executive Summary)
Author(s)Catalent
Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
E&L Challenges in Biologics, Part One
2
E&L Challenges in Biologics, Part Two
3
Chiesi–Aliada Partnership Advances BBB-Crossing Technology for Lysosomal Storage Disorders
4
UK Report Says Persistent Failure to Commercialize R&D Threatens Life Sciences
5
